Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy and Safety of Sitagliptin on Bone Measures in Women Affected by Type 2 Diabetes. a Gender-oriented Approach to Address a Gender-specific Frailty: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) Study.

NCT06770894 is registered in ClinicalTrials.gov with Azienda Policlinico Umberto I as lead sponsor.

NCT NCT06770894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06770894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy and Safety of Sitagliptin on Bone Measures in Women Affected by Type 2 Diabetes. a Gender-oriented Approach to Address a Gender-specific Frailty: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) Study.
Lead sponsor
Azienda Policlinico Umberto I
Phase
Phase 3
Overall status
Completed
Start date
September 24, 2019
Completion date
January 24, 2024
Enrollment
132 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone loss, postmenopausal, diabetes mellitus type 2, osteoporosis